PIB: A Score to Select Sorafenib Treatment Candidates for Hepatocellular Carcinoma in Resource-Limited Settings

Patient Characteristics of Patients with HCC on Sorafeniba Parameter All Patients (n = 127) Complete Survival Data (n = 86) P Value Age 65 (55 - 71) 64 (55 - 71) 0.3 Gender 0.4 Male 70 (89/127) 67 (58/86) Female 30 (38/127) 33 (28/86) Etiology of HCC Infectious 51 (65/127) 54 (47/86) 0.3 HBV + 15 (1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatitis monthly 2018-10, Vol.18 (10)
Hauptverfasser: Leathers, James S, Balderramo, Domingo, Prieto, Jhon, Diehl, Fernando, Gonzalez-Ballerga, Esteban, Ferreiro, Melina R, Carrera, Enrique, Barreyro, Fernando, Diaz-Ferrer, Javier, Singh, Dupinder, Mattos, Angelo Z, Carrilho, Flair, Debes, Jose D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patient Characteristics of Patients with HCC on Sorafeniba Parameter All Patients (n = 127) Complete Survival Data (n = 86) P Value Age 65 (55 - 71) 64 (55 - 71) 0.3 Gender 0.4 Male 70 (89/127) 67 (58/86) Female 30 (38/127) 33 (28/86) Etiology of HCC Infectious 51 (65/127) 54 (47/86) 0.3 HBV + 15 (19/127) 15 (12/86) 0.8 HCV + 38 (48/127) 42 (36/86) 0.2 ASH 32 (41/127) 36 (31/86) 0.08 NASH 17 (21/127) 10 (9/86) 0.01 BCLC stage 0.6 A/B 31 (33/107) 33 (28/86) B/C 69 (74/107) 67 (58/86) Abbreviations: ASH, alcoholic steatohepatitis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis. aContinuous variables expressed as medians (Q1 - Q3) and categorical variables as % (proportion). Many physicians rely on BCLC staging to determine sorafenib eligibility, but as this clinical tool is dependent on advanced imaging modalities, its utility is severely limited. [...]as HCC in areas such as Africa is generally treated by oncologists rather than hepatologists, addressing BCLC criteria represents an additional burden. James S Leathers 1 ; Domingo Balderramo 2 ; Jhon Prieto 3 ; Fernando Diehl 2 ; Esteban Gonzalez-Ballerga 4 ; Melina R Ferreiro 4 ; Enrique Carrera 5 ; Fernando Barreyro 6 ; Javier Diaz-Ferrer 7 ; Dupinder Singh 8 ; Angelo Z. Mattos 9 ; Flair Carrilho 10 ; Jose D. Debes 8 1 School of Medicine, Vanderbilt University, Nashville, USA 2 Department of Gastroenterology, Hospital Privado Universitario de Córdoba, Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina 3 Centro de Enfermedades Hepaticas y Digestivas (CEHYD), Bogota, Colombia 4 Department of Gastroenterology, Hospital Clinicas, Buenos Aires, Argentina 5 Departament of Gastroenterology and Hepatology, Hospital Eugenio Espejo, Quito, Ecuador 6 Consejo Nacional de Investigaciones Científicas y Técnicas, Posadas, Argentina 7 Department of Gastroenterology, Hospital Nacional Edgardo Rebagliati Martins (HNERM), Lima, Peru 8 Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA 9 Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil 10 Department of Gastroenterology, School of Medicine, University of São Paulo, São Paulo, Brazil
ISSN:1735-143X
1735-3408
DOI:10.5812/hepatmon.82345